Literature DB >> 25063237

Comparative study of MRI manifestations of acute and chronic Budd-Chiari syndrome.

Delei Cheng1, Hao Xu, Rong Hua, Kai Xu, Weifei Lv, Xin Lu, Hongtao Du, Qingqiao Zhang.   

Abstract

BACKGROUND: Magnetic resonance imaging (MRI) is able to diagnose Budd-Chiari syndrome (BCS) by distinguishing differential imaging features of acute and chronic forms of the disease. However, the characteristic imaging differences are still not clear as previous data were mostly obtained from scattered small samples instead of large comparative study. AIM: To investigate MRI manifestations of acute and chronic (BCS), and to evaluate the value of MRI for diagnosis of acute and chronic BCS. METHODS AND
RESULTS: We retrospectively compared MRI results of 24 patients with acute and 82 patients with chronic BCS using Mann-Whitney U test for ascites volume, and Fisher's exact test for intrahepatic venous collaterals and extra-hepatic venous collaterals. In the acute group, MRI findings suggested thrombosis in hepatic vein (HV) in all acute patients and additional inferior vena cava (IVC) thrombosis in 5 patients. In the chronic BCS group, 6 and 15 patients showed solitary obstruction either in the IVC or HV, respectively, while 61 patients showed combined IVC and HV obstruction. More patients with acute BCS presented with ascites accompanied with high signals on T2WI from intravenous obstructive lesions. Further, the average maximal spleen diameter in patients with acute BCS, and the ratio of patients with acute BCS developing intrahepatic venous collaterals and extra-hepatic venous collaterals were also lower compared with chronic BCS. All these differences were statistically significant.
CONCLUSION: MRI indicates direct and indirect features of BCS, and therefore enables accurate diagnosis of acute and chronic BCS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25063237     DOI: 10.1007/s00261-014-0193-y

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  3 in total

1.  Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome with diffuse occlusion of hepatic veins.

Authors:  Fuliang He; Hongwei Zhao; Shan Dai; Yingfeng Wu; Lei Wang; Hongdong Huang; Zhendong Yue; Zhenhua Fan; Xiaoqun Dong; Fuquan Liu
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

2.  The Significance of Serum CA-125 Elevation in Chinese Patients with Primary Budd-Chiari Syndrome: A Multicenter Study.

Authors:  De-Lei Cheng; Hao Xu; Wei-Fu Lv; Rong Hua; Hongtao Du; Qing-Qiao Zhang
Journal:  Gastroenterol Res Pract       Date:  2015-09-15       Impact factor: 2.260

3.  The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats.

Authors:  Nan Li; Bin Chen; Run Lin; Ni Liu; Hai-Tao Dai; Ke-Yu Tang; Jian-Yong Yang; Yong-Hui Huang
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-01       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.